St Georges Hospital

The trials here

What the 14 trials at this site are about, from their registry records.

Conditions

• Multiple myeloma4 trials
• Parkinson disease3 trials
• Alzheimer disease2 trials
• Mild cognitive impairment2 trials
• Obesity2 trials
• Dystonia1 trial
• Essential tremor1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• Heart failure1 trial
• Type 2 diabetes1 trial
• Ulcerative colitis1 trial
• Ventricular tachycardia1 trial

Phase

• Phase 35 trials
• Phase 22 trials
• Phase 2/31 trial

Status

• Completed7 trials
• Active, not recruiting4 trials
• Recruiting3 trials

Lead sponsor

• Boston Scientific Corporation3 trials
• Amgen2 trials
• Janssen Research & Development, LLC2 trials
• Novo Nordisk A/S2 trials
• Abbott Medical Devices1 trial
• and 4 more

Running trials

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Amgen· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Amgen· Source

• Recruiting

  Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma

  NCT06762769· Phase 2· University College, London· Source

  Contact: Fenella Willis

• Recruiting

  Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS

  NCT06553625· Boston Scientific Corporation· Source

  Contact: Boston Scientific Clinical Research

• Active, not recruiting

  A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05572515· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

  NCT05160584· Janssen Pharmaceutica N.V., Belgium· Source

• Active, not recruiting

  A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT04033445· Phase 2/3· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Dystonia1 recruiting
• Essential tremor1 recruiting
• Heart failure1 recruiting
• Multiple myeloma1 recruiting
• Obesity1 recruiting
• Parkinson disease1 recruiting

Closed trials

• Completed

  Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

  NCT05232071· Phase 2· Inventiva Pharma· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

  NCT04777396· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· Phase 3· Novo Nordisk A/S· Source

• Completed

  Cartesia eXTend 3D Study

  NCT04577651· Boston Scientific Corporation· Source

• Completed

  FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of VT Study

  NCT03490201· Abbott Medical Devices· Source

• Completed

  A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

  NCT03106324· Celgene· Source

• Recruiting

  Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

  NCT02071134· Boston Scientific Corporation· Source

  Contact: Heleen Scholtes